focus -WSS

focus

author：Wikipedia 2025-09-28 02:32:51 - browse：6127

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Some top drug companies are starting to take action on climate

hotspot

WSS

The biotech scorecard for Q4: 16 stock

WHO recommends second malaria vaccine

Some top drug companies are starting to take action on climate

Congressmen charge Covid hearing ‘could have been an email’

Biden administration opens offers in Medicare drug price negotiations

The Karikó problem: Lessons for funding basic research

leisure time

focus

focus

Medical leaders decry Supreme Court decision on affirmative action

Quicker fix for pulse oximeters urged during FDA public meeting

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare innovation center doesn’t save money, experts say

State Dept. review finds Biden bears some blame for Afghanistan failures

The biotech scorecard for Q4: 16 stock

FDA approval of Sarepta Duchenne genetic therapy gives me hope

General Catalyst, Summa Health deal will turn on physician buy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Congress extends some pandemic preparedness programs

knowledge

General Catalyst, Summa Health deal will turn on physician buy

Cybersecurity threat forces Lurie Children's to take systems offline

CRISPR base editing slashes cholesterol levels in monkeys

The real point of Kenneth Smith’s execution by nitrogen gas

CDC picks Alphabet's Verily for wasterwater surveillance contract

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

hotspot

leisure time

hotspot

focus